CFSB Bancorp Q1 EPS $0.10

CFSB Bancorp (NASDAQ:CFSB) reported quarterly earnings of $0.10 per share.

byMichael Horton

October 21, 2022

1 minute read

CFSB Bancorp (NASDAQ:CFSB) reported quarterly earnings of $0.10 per share.

FDA
News

Sarepta Therapeutics Says Co’s SRP-9001 Shows Sustained Functional Improvements In Multiple Studies Of Patients With Duchenne

By Benzinga Newsdesk

October 11, 9:15 AM

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new analyses and functional data from its SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) development

SRPT

Aptar Pharma Pays Pharmaxis $5M to Acquire Orbital Technology

By Charles Gross

August 4, 4:52 AM

Clinical stage drug developer Pharmaxis (ASX: PXS) today announced that Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, has exercised the option to acquire the worldwide rights to Pharmaxis' proprietary inhaler Orbital, a unique device designed to deliver high payload dry powder to the lungs.

ATR

Eastman Chemical (EMN) To Post Q2 Earnings: Factors At Play

By Zacks

July 26, 3:05 PM

Eastman Chemical Company (NYSE: EMN) is set to release second-quarter 2022 results after the closing bell on Jul 28.

ALB

Weave Signs First-Of-Its-Kind Integration Partnership With Provet Cloud; Terms Not Disclosed

By Benzinga Newsdesk

April 26, 11:40 AM

Weave (NYSE:WEAV), the all-in-one customer communication platform for small business, today announced it has signed an integration partnership agreement with Provet Cloud, by Nordhealth, a practice management solution

WEAV

CFSB Bancorp Q1 EPS $0.10

Related Posts

Sarepta Therapeutics Says Co’s SRP-9001 Shows Sustained Functional Improvements In Multiple Studies Of Patients With Duchenne

Aptar Pharma Pays Pharmaxis $5M to Acquire Orbital Technology

Eastman Chemical (EMN) To Post Q2 Earnings: Factors At Play

Weave Signs First-Of-Its-Kind Integration Partnership With Provet Cloud; Terms Not Disclosed